Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai: Record-High Profits Driven by Aricept
November 8, 2010
- Korosho to Take Advantage of Kohdo-Iryo System to Eliminate Drug Lag
November 8, 2010
- Chugai Applies for Pegasys, Copegus Combination Therapy
November 8, 2010
- MTPC: Remicade Drives Business with 29% Increases in Sales
November 8, 2010
- Eisai to Mobilize All of Its 1,400 MRs to Promote Bendamustine from SymBio
November 8, 2010
- FDA Approves Herceptin for Metastatic Stomach Cancer
November 8, 2010
- DSP: Sales Up 42.6% Due to Addition of Sunovion
November 8, 2010
- Byetta Approved as Japan's 2nd GLP-1 Agonist in Japan: Eli Lilly
November 8, 2010
- Roche Applies for Actemra for sJIA in the US, EU
November 8, 2010
- AZ, Daiichi Sankyo to Copromote Esomeprazole in Japan
November 8, 2010
- Samsca Approved for Excess Water Retention: Otsuka
November 8, 2010
- PhRMA Welcomes Korosho's Vaccine Committee Report
November 8, 2010
- BI Inaugurates New Inhaler Factory
November 1, 2010
- Japan Can Contribute to Global Development by Earlier Participation: Dr Yoshikawa of Eli Lilly Japan
November 1, 2010
- 5-Fold Increase in Pollen Counts Expected in Spring 2011
November 1, 2010
- Japan's First IP Fund Starts Operation
November 1, 2010
- Diagnostic Imaging Is Japan's Advantage: Ms Sawada of Shionogi
November 1, 2010
- Catalent Embarks on Master Cell Bank Development Business in Japan
November 1, 2010
- Vidaza Recommended for Approval
November 1, 2010
- “Medical Innovation Center Scheme”Proposed by Dr Kayama
November 1, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…